Due to the limitations of tumor size, relationship with large blood vessels and biliary tract, patients with “small hepatocellular carcinoma” in special location, patients with middle and late stage hepatocellular carcinoma with huge tumors, and patients with multiple metastatic lesions in stage IIIb or IV in pathological staging are often deprived of the opportunity of surgical treatment. Patients with the above-mentioned conditions should prefer argon helium supercooling knife minimally invasive treatment, which directly destroys the cellular structure of tumor tissue through physical freezing and thawing means in a short period of time, induces necrosis and apoptosis of tumor tissue in the center of freezing, and closes the small blood vessels that supply tumor. Combined with interventional treatment, the two can inhibit the growth of hepatocellular carcinoma in a short period of time for patients with giant liver cancer. Since most primary hepatocellular carcinomas are unresectable large hepatocellular carcinomas and are mostly accompanied by cancer thrombosis in the portal vein system inside and outside the liver, the recurrence rate is still as high as 60% within 1 year and the 3-year survival rate is less than 30% after traditional radiotherapy. The recurrence of liver cancer after surgery mainly comes from micro-metastasis of early liver cancer, therefore, the recurrence prevention treatment after liver cancer surgery is very crucial, because traditional radiotherapy has great toxic side effects and easily causes liver function damage. It can stop and control the further development and metastasis of tumor. It can further improve and consolidate the curative effect of liver cancer and reduce recurrence by solving the subclinical metastasis which is difficult to be solved by conventional therapy. According to clinical statistics, cellular immunotherapy can better prevent recurrence of hepatocellular carcinoma after surgery. 9 cases of stage IV patients had an average survival of 20 months after more than 3 cycles of postoperative treatment, and the recurrence rate was 22.2% within 1 year. One patient with advanced hepatocellular carcinoma with lung metastasis was in partial remission after CIK cell therapy, and has survived for more than 2 years after imaging.